Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy

C. Ponticelli, P. Zucchelli, E. Imbasciati, L. Cagnoli, C. Pozzi, P. Passerini, C. Grassi, D. Limido, S. Pasquali, T. Volpini

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Sixty-seven adults with idiopathic membranous nephropathy and the nephrotic syndrome were randomly assigned to symptomatic treatment only or to a six-month course of methylprednisolone alternated with chlorambucil every other month. Patients were followed for one to seven years. At the end of follow-up (mean of 31.4 ± 18.2 months for the treated group and 37.0 ± 22.0 for the control group) 23 of 32 treated patients were in complete or partial remission, as compared with 9 of 30 control patients (P = 0.001). Twelve of the treated patients were in complete remission, as compared with only two of the controls. In the treated group there were no changes in renal function during follow-up, whereas in the control group the reciprocal of the plasma creatinine level, which is proportional to the creatinine clearance, decreased significantly (P = 0.00017) after two years of follow-up. Side effects were minimal in all treated patients except two, who were dropped from the study because of peptic ulcer and gastric intolerance to chlorambucil. We conclude that steroid and chlorambucil treatment for six months favors remission of the nephrotic syndrome in adults with idiopathic membranous nephropathy and can preserve renal function for at least some years.

Original languageEnglish
Pages (from-to)946-950
Number of pages5
JournalNew England Journal of Medicine
Volume310
Issue number15
Publication statusPublished - 1984

Fingerprint

Chlorambucil
Membranous Glomerulonephritis
Methylprednisolone
Nephrotic Syndrome
Creatinine
Kidney
Control Groups
Peptic Ulcer
Stomach
Steroids
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ponticelli, C., Zucchelli, P., Imbasciati, E., Cagnoli, L., Pozzi, C., Passerini, P., ... Volpini, T. (1984). Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. New England Journal of Medicine, 310(15), 946-950.

Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. / Ponticelli, C.; Zucchelli, P.; Imbasciati, E.; Cagnoli, L.; Pozzi, C.; Passerini, P.; Grassi, C.; Limido, D.; Pasquali, S.; Volpini, T.

In: New England Journal of Medicine, Vol. 310, No. 15, 1984, p. 946-950.

Research output: Contribution to journalArticle

Ponticelli, C, Zucchelli, P, Imbasciati, E, Cagnoli, L, Pozzi, C, Passerini, P, Grassi, C, Limido, D, Pasquali, S & Volpini, T 1984, 'Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy', New England Journal of Medicine, vol. 310, no. 15, pp. 946-950.
Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. New England Journal of Medicine. 1984;310(15):946-950.
Ponticelli, C. ; Zucchelli, P. ; Imbasciati, E. ; Cagnoli, L. ; Pozzi, C. ; Passerini, P. ; Grassi, C. ; Limido, D. ; Pasquali, S. ; Volpini, T. / Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. In: New England Journal of Medicine. 1984 ; Vol. 310, No. 15. pp. 946-950.
@article{99eca192be1e44d0a03e51ebe81fbd27,
title = "Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy",
abstract = "Sixty-seven adults with idiopathic membranous nephropathy and the nephrotic syndrome were randomly assigned to symptomatic treatment only or to a six-month course of methylprednisolone alternated with chlorambucil every other month. Patients were followed for one to seven years. At the end of follow-up (mean of 31.4 ± 18.2 months for the treated group and 37.0 ± 22.0 for the control group) 23 of 32 treated patients were in complete or partial remission, as compared with 9 of 30 control patients (P = 0.001). Twelve of the treated patients were in complete remission, as compared with only two of the controls. In the treated group there were no changes in renal function during follow-up, whereas in the control group the reciprocal of the plasma creatinine level, which is proportional to the creatinine clearance, decreased significantly (P = 0.00017) after two years of follow-up. Side effects were minimal in all treated patients except two, who were dropped from the study because of peptic ulcer and gastric intolerance to chlorambucil. We conclude that steroid and chlorambucil treatment for six months favors remission of the nephrotic syndrome in adults with idiopathic membranous nephropathy and can preserve renal function for at least some years.",
author = "C. Ponticelli and P. Zucchelli and E. Imbasciati and L. Cagnoli and C. Pozzi and P. Passerini and C. Grassi and D. Limido and S. Pasquali and T. Volpini",
year = "1984",
language = "English",
volume = "310",
pages = "946--950",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "15",

}

TY - JOUR

T1 - Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy

AU - Ponticelli, C.

AU - Zucchelli, P.

AU - Imbasciati, E.

AU - Cagnoli, L.

AU - Pozzi, C.

AU - Passerini, P.

AU - Grassi, C.

AU - Limido, D.

AU - Pasquali, S.

AU - Volpini, T.

PY - 1984

Y1 - 1984

N2 - Sixty-seven adults with idiopathic membranous nephropathy and the nephrotic syndrome were randomly assigned to symptomatic treatment only or to a six-month course of methylprednisolone alternated with chlorambucil every other month. Patients were followed for one to seven years. At the end of follow-up (mean of 31.4 ± 18.2 months for the treated group and 37.0 ± 22.0 for the control group) 23 of 32 treated patients were in complete or partial remission, as compared with 9 of 30 control patients (P = 0.001). Twelve of the treated patients were in complete remission, as compared with only two of the controls. In the treated group there were no changes in renal function during follow-up, whereas in the control group the reciprocal of the plasma creatinine level, which is proportional to the creatinine clearance, decreased significantly (P = 0.00017) after two years of follow-up. Side effects were minimal in all treated patients except two, who were dropped from the study because of peptic ulcer and gastric intolerance to chlorambucil. We conclude that steroid and chlorambucil treatment for six months favors remission of the nephrotic syndrome in adults with idiopathic membranous nephropathy and can preserve renal function for at least some years.

AB - Sixty-seven adults with idiopathic membranous nephropathy and the nephrotic syndrome were randomly assigned to symptomatic treatment only or to a six-month course of methylprednisolone alternated with chlorambucil every other month. Patients were followed for one to seven years. At the end of follow-up (mean of 31.4 ± 18.2 months for the treated group and 37.0 ± 22.0 for the control group) 23 of 32 treated patients were in complete or partial remission, as compared with 9 of 30 control patients (P = 0.001). Twelve of the treated patients were in complete remission, as compared with only two of the controls. In the treated group there were no changes in renal function during follow-up, whereas in the control group the reciprocal of the plasma creatinine level, which is proportional to the creatinine clearance, decreased significantly (P = 0.00017) after two years of follow-up. Side effects were minimal in all treated patients except two, who were dropped from the study because of peptic ulcer and gastric intolerance to chlorambucil. We conclude that steroid and chlorambucil treatment for six months favors remission of the nephrotic syndrome in adults with idiopathic membranous nephropathy and can preserve renal function for at least some years.

UR - http://www.scopus.com/inward/record.url?scp=0021345894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021345894&partnerID=8YFLogxK

M3 - Article

C2 - 6366560

AN - SCOPUS:0021345894

VL - 310

SP - 946

EP - 950

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 15

ER -